Kura Oncology Inc (NASDAQ: KURA) on Friday, plunged -1.16% from the previous trading day, before settling in for the closing price of $11.17. Within the past 52 weeks, KURA’s price has moved between $9.06 and $24.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -14.68%. With a float of $63.70 million, this company’s outstanding shares have now reached $74.35 million.
Let’s look at the performance matrix of the company that is accounted for 142 employees. In terms of profitability, gross margin is 48.82%, operating margin of -17126.14%, and the pretax margin is -15555.28%.
Kura Oncology Inc (KURA) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Kura Oncology Inc is 18.08%, while institutional ownership is 91.87%. The most recent insider transaction that took place on Nov 18 ’24, was worth 8,434. In this transaction Chief Operating Officer of this company sold 526 shares at a rate of $16.03, taking the stock ownership to the 23,184 shares. Before that another transaction happened on Nov 18 ’24, when Company’s Officer proposed sale 526 for $15.99, making the entire transaction worth $8,410.
Kura Oncology Inc (KURA) Latest Financial update
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.55 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.54) by -0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.67 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -14.68% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 19.93% during the next five years compared to -3.94% drop over the previous five years of trading.
Kura Oncology Inc (NASDAQ: KURA) Trading Performance Indicators
Kura Oncology Inc (KURA) is currently performing well based on its current performance indicators. A quick ratio of 11.47 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.36, a number that is poised to hit -0.57 in the next quarter and is forecasted to reach -2.07 in one year’s time.
Technical Analysis of Kura Oncology Inc (KURA)
Kura Oncology Inc (NASDAQ: KURA) saw its 5-day average volume 4.09 million, a positive change from its year-to-date volume of 1.04 million. As of the previous 9 days, the stock’s Stochastic %D was 20.67%. Additionally, its Average True Range was 1.11.
During the past 100 days, Kura Oncology Inc’s (KURA) raw stochastic average was set at 9.86%, which indicates a significant decrease from 13.53% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 194.86% in the past 14 days, which was higher than the 82.79% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.11, while its 200-day Moving Average is $19.75. Nevertheless, the first resistance level for the watch stands at $11.23 in the near term. At $11.43, the stock is likely to face the second major resistance level. The third major resistance level sits at $11.60. If the price goes on to break the first support level at $10.86, it is likely to go to the next support level at $10.69. The third support level lies at $10.49 if the price breaches the second support level.
Kura Oncology Inc (NASDAQ: KURA) Key Stats
Market capitalization of the company is 848.52 million based on 77,764K outstanding shares. Right now, sales total 0 K and income totals -152,630 K. The company made 0 K in profit during its latest quarter, and -54,400 K in sales during its previous quarter.
